Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05940493 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib in Newly Diagnosed Meningioma Patients
A Phase 2 study of Meningioma, sponsored by Nader Sanai.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05940493 is a Phase 2 study of Meningioma that is actively recruiting participants, run by Nader Sanai. The registered enrollment target is 72 participants, below the 96-participant average among 21 other Meningioma trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05940493, a Phase 2 study of Meningioma, is actively recruiting participants, sponsored by Nader Sanai.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors. Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy. This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Abemaciclib
Study Locations (1)
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2030-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05940493
The ClinicalTrials.gov registry entry for NCT05940493 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 21 other Meningioma trials with a reported enrollment target (25% lower). The listed sponsor is Nader Sanai, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05940493 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05940493 about?
NCT05940493 is a clinical study titled "Abemaciclib in Newly Diagnosed Meningioma Patients". This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors. Participants who consent to the trial will have surgical tissue c...
What is the current status of trial NCT05940493?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2025-03-24. Estimated completion is 2030-09.
What conditions does trial NCT05940493 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT05940493?
The interventions under investigation include: Placebo (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT05940493?
This trial is sponsored by Nader Sanai, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05940493 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
Monthly SOM230C for Recurrent or Progressive Meningioma
COMPLETED · Phase 2
-
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.